share_log

bluebird bio | 8-K: Current report

bluebird bio | 8-K: Current report

bluebird bio | 8-K：重大事件
美股sec公告 ·  06/24 08:05
Moomoo AI 已提取核心信息
On June 20, 2024, bluebird bio, Inc., a biotechnology company listed on the Nasdaq Stock Market under the trading symbol BLUE, announced the appointment of Michael Cloonan to its board of directors. Cloonan was appointed as a Class I director and his term became effective on the same day. As part of his compensation, Cloonan will receive an annual retainer of $45,000, along with an initial award of a stock option to purchase 74,775 shares and 37,350 restricted stock units of the company's common stock. These equity awards will vest over a period of three years in annual installments. Additionally, Cloonan will be entering into the company's standard indemnification agreement for directors and officers. The company confirmed that Cloonan has no familial ties with any current director or executive officer and is not involved in any transaction with the company that would necessitate disclosure under SEC regulations. The appointment is part of the company's ongoing governance and leadership structure.
On June 20, 2024, bluebird bio, Inc., a biotechnology company listed on the Nasdaq Stock Market under the trading symbol BLUE, announced the appointment of Michael Cloonan to its board of directors. Cloonan was appointed as a Class I director and his term became effective on the same day. As part of his compensation, Cloonan will receive an annual retainer of $45,000, along with an initial award of a stock option to purchase 74,775 shares and 37,350 restricted stock units of the company's common stock. These equity awards will vest over a period of three years in annual installments. Additionally, Cloonan will be entering into the company's standard indemnification agreement for directors and officers. The company confirmed that Cloonan has no familial ties with any current director or executive officer and is not involved in any transaction with the company that would necessitate disclosure under SEC regulations. The appointment is part of the company's ongoing governance and leadership structure.
2024年6月20日，生物技术公司bluebird bio在纳斯达克证券交易市场上市，交易代码为BLUE，并宣布任命Michael Cloonan为其董事会成员。Cloonan被任命为一级董事，他的任期当天生效。作为他的报酬，Cloonan将获得45,000美元的年度保证金，以及用于购买公司普通股的74,775股股票期权和37,350个受限制的股票单位的初始奖励，这些股权奖励将在三年内每年分期归属。此外，Cloonan将进入公司为董事和高管提供的标准赔偿协议。公司确认Cloonan与任何现任董事或高管没有家族关系，并且未参与与公司有必要根据SEC法规披露的任何交易。此次任命是公司持续进行的治理和领导架构的一部分。
2024年6月20日，生物技术公司bluebird bio在纳斯达克证券交易市场上市，交易代码为BLUE，并宣布任命Michael Cloonan为其董事会成员。Cloonan被任命为一级董事，他的任期当天生效。作为他的报酬，Cloonan将获得45,000美元的年度保证金，以及用于购买公司普通股的74,775股股票期权和37,350个受限制的股票单位的初始奖励，这些股权奖励将在三年内每年分期归属。此外，Cloonan将进入公司为董事和高管提供的标准赔偿协议。公司确认Cloonan与任何现任董事或高管没有家族关系，并且未参与与公司有必要根据SEC法规披露的任何交易。此次任命是公司持续进行的治理和领导架构的一部分。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息